Plasma VEGF - a candidate biomarker for response to treatment with bevacizumab in HHT patients.
CONCLUSIONS: The role of plasma VEGF as a potential predictive biomarker for therapeutic response to bevacizumab treatment warrants further investigation in larger prospective studies.
PMID: 31681913 [PubMed - as supplied by publisher]
Source: Rhinology - Category: ENT & OMF Tags: Rhinology Source Type: research
More News: Avastin | Bleeding | ENT & OMF | Epistaxis (Nosebleeds) | Hereditary Hemorrhagic Telangiectasia | Study